A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
一项 I 期研究旨在确定双重 VEGFR 和 FGFR 抑制剂 brivanib 在晚期或转移性实体瘤患者中的安全性、药代动力学和药效学。
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdq599
Jonker, D J; Rosen, L S; Sawyer, M B; de Braud, F; Wilding, G; Sweeney, C J; Jayson, G C; McArthur, G A; Rustin, G; Goss, G; Kantor, J; Velasquez, L; Syed, S; Mokliatchouk, O; Feltquate, D M; Kollia, G; Nuyten, D S A; Galbraith, S